Immunome Inc.

IMNM

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
SEC CIK: 0001472012

SEC filings (opens in a new tab)

In the last 90 days, Immunome Inc. insiders filed 0 open-market purchases and 7 sales; 202 institutions reported holding it in 13F filings for Q2 2026, worth $2.50B in total; no superinvestor holds it.

Q3 2025 vs. Q2 2025

How the institutions holding Immunome Inc. changed between Q2 2025 and Q3 2025.

All holders in Q3 2025 All holders in Q2 2025

13F holders of IMNM: Q2 2025 compared with Q3 2025
Measure	Q2 2025	Of which not filed for Q3 2025	Q3 2025	Change
Holders	142	1	153	+12
Shares	79.4M	43.0K	91.4M	+12.0M (+15.1%)
Value	$738.7M	$399.5K	$1.07B	+$331.8M (+44.9%)

1 institution that held it in Q2 2025 haven't filed for Q3 2025 yet. Not filing isn't selling, so the changes leave them out.

New holders (27)

Institutions that held Immunome Inc. at the end of Q3 2025 but not at the end of Q2 2025.

Institutions new to IMNM in Q3 2025
Institution	Shares	Value	% of portfolio
Caption Management, LLC	1,040,700	$12.2M	0.71%
Citadel Advisors LLC	841,138	$9.85M	0.01%
Pivotal bioVenture Partners Investment Advisor LLC	502,512	$5.88M	3.40%
Parkman Healthcare Partners LLC	351,131	$4.11M	0.45%
AXA Investment Managers S.A.	180,056	$2.11M	0.01%
Sphera Funds Management Ltd.	147,200	$1.72M	0.41%
Gilder Gagnon Howe & Co LLC	133,112	$1.56M	0.02%
Schonfeld Strategic Advisors LLC	73,058	$855.5K	0.01%
XTX Topco Ltd	70,514	$825.7K	0.04%
American Century Companies Inc	63,306	$741.3K	0.00%
J. Goldman & Co LP	61,344	$718.3K	0.03%
Jane Street Group, LLC	60,708	$710.9K	0.00%
Susquehanna Portfolio Strategies, LLC	44,164	$517.2K	0.01%
CI Private Wealth, LLC	43,203	$505.9K	0.00%
Cetera Investment Advisers	25,361	$297.0K	0.00%
Qube Research & Technologies Ltd	25,217	$295.3K	0.00%
Palumbo Wealth Management LLC	21,844	$255.8K	0.08%
Pictet Asset Management Holding SA	14,619	$171.2K	0.00%
Velan Capital Investment Management LP	10,000	$117.1K	0.11%
Quarry LP	10,000	$117.1K	0.03%
SG Americas Securities, LLC	8,769	$103.0K	0.00%
Russell Investments Group, Ltd.	6,482	$75.9K	0.00%
BIT Capital GmbH	5,927	$69.4K	0.00%
Assetmark, Inc	3,364	$39.4K	0.00%
Optiver Holding B.V.	554	$6.49K	0.00%
Steigerwald, Gordon & Koch Inc.	200	$2.34K	0.00%
SRS Capital Advisors, Inc.	120	$1.41K	0.00%

Sold out (15)

Institutions that held Immunome Inc. at the end of Q2 2025 and filed for Q3 2025 without it.

Institutions that sold out of IMNM in Q3 2025
Institution	Shares, Q2 2025	Value, Q2 2025
Natixis	229,305	$2.13M
AXA S.A.	179,519	$1.67M
Balyasny Asset Management LLC	109,754	$1.02M
Y-Intercept (Hong Kong) Ltd	85,227	$792.6K
ExodusPoint Capital Management, LP	81,873	$761.0K
Main Management ETF Advisors, LLC	76,944	$716.0K
Two Sigma Investments, LP	26,654	$247.9K
Cantor Fitzgerald, L. P.	21,000	$195.3K
Man Group plc	20,614	$191.7K
Whalen Wealth Management Inc.	13,722	$127.6K
Verition Fund Management LLC	12,875	$119.7K
SummitTX Capital, L.P.	10,695	$99.5K
Caitong International Asset Management Co., Ltd	610	$5.67K
US Bancorp	21	$195
EverSource Wealth Advisors, LLC	8	$74

Not filed for Q3 2025 yet (1)

Institutions that held Immunome Inc. at the end of Q2 2025 and haven't filed a 13F for Q3 2025. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding IMNM in Q2 2025 that haven't filed for Q3 2025
Institution	Shares, Q2 2025	Value, Q2 2025
Northeast Financial Consultants Inc	42,953	$399.5K